1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Colestipol Hydrochloride for Oral Suspension

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>COLESTID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use</td>
<td>Pharmaceutical product for the treatment of high cholesterol (hyperlipidemia).</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: Light orange Granules

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

- **Short Term:** May cause irritation (based on components).
- **Long Term:** Animal studies indicate that this material may cause adverse effects on the endocrine system.

Known Clinical Effects:

- Adverse effects most commonly reported in clinical use include gastrointestinal disturbances: flatulence, vomiting, nausea, diarrhea, abdominal pain, constipation, dizziness and headache.


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerin, USP</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Colestipol Hydrochloride</td>
<td>37296-80-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>67</td>
</tr>
</tbody>
</table>
### 4. FIRST AID MEASURES

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:**
Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:**
Formation of toxic gases is possible during heating or fire.

**Fire Fighting Procedures:**
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:**
Fine particles (such as dust and mists) may fuel fires/explosions.

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:**
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:**
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:**
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Additional Consideration for Large Spills:**
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

General Handling: Avoid generating airborne dust. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Glycerin, USP

<table>
<thead>
<tr>
<th>Source</th>
<th>Threshold Limit Value (TWA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH Threshold Limit Value</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>ACGIH OELs - Notice of Intended Changes</td>
<td>Listed</td>
</tr>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td>20 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>

Colestipol Hydrochloride

<table>
<thead>
<tr>
<th>Source</th>
<th>Threshold Limit Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer OEL TWA-8 Hr:</td>
<td>3000µg/m³</td>
</tr>
</tbody>
</table>

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Granules
Molecular Formula: Mixture
Color: Light orange
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Veltol (maltol FCC)
- Rat Oral LD50 1410 mg/kg
- Mouse Oral LD50 550 mg/kg

Mannitol
- Rat Oral LD 50 13500 mg/kg
- Mouse Oral LD 50 22 g/kg

Colestipol Hydrochloride
- Rat Oral LD50 >1000 mg/kg
- Mouse Oral LD50 >1000 mg/kg
- Rat Intrapertitoneal LD50 >4000 mg/kg
- Mouse Intraperitoneal LD50 >4000 mg/kg

Glycerin, USP
- Mouse Oral LD50 4090 mg/kg
- Rat Oral LD50 12.6 g/kg
- Rabbit Dermal LD50 > 10 g/kg
- Rat Inhalation LC50 1hr > 570 mg/m³
- Rat Dermal LD 50 > 21.9 g/kg

Acute Toxicity Comments: A greater than symbol (> ) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Colestipol Hydrochloride
- Eye Irritation Rabbit Mild
- Skin Irritation Rabbit Non-irritating

Glycerin, USP
- Eye Irritation Rabbit Mild
11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Colestipol Hydrochloride
1 Month(s)  Rat  Oral  300 mg/kg/day  NOAEL  No effects at maximum dose
14 Day(s)  Rabbit  Oral  4000 mg/kg/day  NOAEL  No effects at maximum dose
1 Month(s)  Dog  Oral  3000 mg/kg/day  LOAEL  None identified
18 Month(s)  Rat  Oral  2000 mg/kg/day  NOAEL  No effects at maximum dose
1 Year(s)  Dog  Oral  500 mg/kg/day  LOAEL  None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Colestipol Hydrochloride
Reproductive & Fertility  Rat  Oral  1000 mg/kg/day  NOAEL  No effects at maximum dose
Embryo / Fetal Development  Rat  Oral  1000 mg/kg/day  NOAEL  Not Teratogenic
Embryo / Fetal Development  Rabbit  Oral  1000 mg/kg/day  NOAEL  Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Colestipol Hydrochloride
Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Colestipol Hydrochloride
18 Month(s)  Rat  Oral  2000 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:  Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
Oncorhyncus mykiss (Rainbow Trout)  LD50  96 Hours  50 mg/L
Daphnia magna (Water Flea)  EC50  24 Hours  >500 mg/L

Aquatic Toxicity Comments:  A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Glycerin, USP
California Proposition 65
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex V - Exemptions from the obligations of Register: Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern

EU EINECS/ELINCS List
200-289-5

Beta Carotene
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 230-636-6

Flavor blend
California Proposition 65 Not Listed

Mannitol
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>REACH - Annex IV - Exemptions from the obligations of Register:</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylcellulose</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>200-711-8</td>
</tr>
<tr>
<td>Veltol (maltol FCC)</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>204-271-8</td>
</tr>
<tr>
<td>Aspartame</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>245-261-3</td>
</tr>
<tr>
<td>Colestipol Hydrochloride</td>
<td>Not Listed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td>201-069-1</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 7 - Handling and Storage. Updated Section 10 - Stability and Reactivity.


Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.